Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio
Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.
AMPH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amphastar Pharmaceuticals Inc. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Amphastar Pharmaceuticals Inc, consider:
Its compound free cash flow growth rate, as measured over the past 4.98 years, is -0.18% -- higher than only 10.64% of stocks in our DCF forecasting set.
The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 18% of the free cash flow producing stocks we're observing.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMPH, try ALC, CSII, ELAN, HAPP, and MEDS.